mrjСовременная ревматологияModern Rheumatology Journal1996-70122310-158XIMA-PRESS, LLC10.14412/1996-7012-2025-1-110-115mrj-1711Research ArticleКЛИНИЧЕСКИЕ НАБЛЮДЕНИЯCLINICAL OBSERVATIONSДифференциальная диагностика нетравматического гемартроза коленного сустава (случай из практики)Differential diagnosis of non-traumatic knee hemarthrosis (case report)РоскидайлоА. А.RoskidayloA. A.

Анастасия Александровна Роскидайло, 

115522, Москва, Каширское шоссе, 34А

Anastasia Aleksandrovna Roskidaylo,

34A, Kashirskoe Shosse, Moscow 115522

roskidailo@mail.ruФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation202517022025191110115Copyright © Роскидайло А.А., 20252025Роскидайло А.А.Roskidaylo A.A.This work is licensed under a Creative Commons Attribution 4.0 License.https://mrj.ima-press.net/mrj/article/view/1711

Гемартроз (ГА) коленного сустава (КС) нетравматического происхождения нечасто встречается в практике травматологаортопеда. Для дифференциальной диагностики этой патологии требуются тщательный сбор анамнеза и клинический осмотр пациента, а пункция КС лишь подтвердит наличие крови в суставе. Диагностическая артроскопия с биопсией синовиальной оболочки помогает уточнить диагноз. Наиболее частыми причинами нетравматического ГА являются опухоли сосудистого или синовиального генеза, метастазы опухолей, а также прием больших доз антикоагулянтов в сочетании с сосудистой мальформацией. Представлено клиническое наблюдение развития симптомов нетравматического ГА на фоне приема антикоагулянтов, при этом задачей ортопеда было выявление истинной причины заболевания.

Hemarthrosis (HA) of the knee of non-traumatic origin is rarely encountered in the practice of a traumatologist-orthopedic surgeon. The differential diagnosis of this pathology requires a thorough medical history tacking and clinical examination of the patient, and a knee joint aspiration can only confirm the presence of blood in the joint. A diagnostic arthroscopy with a synovial biopsy helps to clarify the diagnosis. The most common causes of non-traumatic HA are tumors of vascular or synovial origin, tumor metastases and the use of high-dose anticoagulants in combination with a vascular malformation.

A clinical observation of the development of symptoms of non-traumatic HA on the background of anticoagulant use is presented, where the task of the orthopedic surgeon was to identify the true cause of the disease.

гемартрозколенный суставпигментный виллонодулярный синовитhemarthrosisknee jointpigmented villonodular synovitiReferencesBaker CL. Acute hemarthrosis of the knee. J Med Assoc Ga. 1992 Jun;81(6):301-5.Baker CL. Acute hemarthrosis of the knee. J Med Assoc Ga. 1992 Jun;81(6):301-5.Adalberth T, Roos H, Lauren M, et al. Magnetic resonance imaging, scintigraphy, and arthroscopic evaluation of traumatic hemarthrosis of the knee. Am J Sports Med. 1997 Mar-Apr;25(2):231-7. doi: 10.1177/036354659702500217.Adalberth T, Roos H, Lauren M, et al. Magnetic resonance imaging, scintigraphy, and arthroscopic evaluation of traumatic hemarthrosis of the knee. Am J Sports Med. 1997 Mar-Apr;25(2):231-7. doi: 10.1177/036354659702500217.Olsson O, Isacsson A, Englund M, Frobell RB. Epidemiology of intra- and periarticular structural injuries in traumatic knee joint hemarthrosis – data from 1145 consecutive knees with subacute MRI. Osteoarthritis Cartilage. 2016 Nov;24(11):1890-1897. doi: 10.1016/j.joca.2016.06.006. Epub 2016 Jun 29.Olsson O, Isacsson A, Englund M, Frobell RB. Epidemiology of intra- and periarticular structural injuries in traumatic knee joint hemarthrosis – data from 1145 consecutive knees with subacute MRI. Osteoarthritis Cartilage. 2016 Nov;24(11):1890-1897. doi: 10.1016/j.joca.2016.06.006. Epub 2016 Jun 29.Lombardi M, Cardenas AC. Hemarthrosis. Statpearls Last Update. Treasure Island: StatPearls Publishing; 2020.Lombardi M, Cardenas AC. Hemarthrosis. Statpearls Last Update. Treasure Island: StatPearls Publishing; 2020.Kawamura H, Ogata K, Miura H, et al. Spontaneous hemarthrosis of the knee in the elderly: etiology and treatment. Arthroscopy. 1994 Apr;10(2):171-5. doi: 10.1016/s0749-8063(05)80089-1.Kawamura H, Ogata K, Miura H, et al. Spontaneous hemarthrosis of the knee in the elderly: etiology and treatment. Arthroscopy. 1994 Apr;10(2):171-5. doi: 10.1016/s0749-8063(05)80089-1.Worland RL, Jessup DE. Recurrent hemarthrosis after total knee arthroplasty. J Arthroplasty. 1996 Dec;11(8):977-8. doi: 10.1016/s0883-5403(96)80144-6.Worland RL, Jessup DE. Recurrent hemarthrosis after total knee arthroplasty. J Arthroplasty. 1996 Dec;11(8):977-8. doi: 10.1016/s0883-5403(96)80144-6.Garner HW, Bestic JM. Benign synovial tumors and proliferative processes. Semin Musculoskelet Radiol. 2013 Apr;17(2):177-8. doi: 10.1055/s-0033-1343095. Epub 2013 May 14.Garner HW, Bestic JM. Benign synovial tumors and proliferative processes. Semin Musculoskelet Radiol. 2013 Apr;17(2):177-8. doi: 10.1055/s-0033-1343095. Epub 2013 May 14.Jaffe HL, Lichstenstein L, Sutro CJ. Pigmented villonodular synovitis, bursitis and tenosynovitis. Arch Pathol. 1941;31:731-65.Jaffe HL, Lichstenstein L, Sutro CJ. Pigmented villonodular synovitis, bursitis and tenosynovitis. Arch Pathol. 1941;31:731-65.de Saint Aubain Somerhausen N, van de Rijn M. Tenosynovial giant cell tumour, diffuse type. In: Fletcher CDM, Bridge JA, Hogendoorn P, Mertens F, editors. WHO Classification of Tumours of Soft Tissue and Bone. Vol. 5. 4th ed. International Agency for Research on Cancer (IARC); 2013. P. 100–3.de Saint Aubain Somerhausen N, van de Rijn M. Tenosynovial giant cell tumour, diffuse type. In: Fletcher CDM, Bridge JA, Hogendoorn P, Mertens F, editors. WHO Classification of Tumours of Soft Tissue and Bone. Vol. 5. 4th ed. International Agency for Research on Cancer (IARC); 2013. P. 100–3.Staals EL, Ferrari S, Donati DM, Palmerini E. Diffuse-type tenosynovial giant cell tumour: current treatment concepts and future perspectives. Eur J Cancer. 2016 Aug: 63:34-40. doi: 10.1016/j.ejca.2016.04.022. Epub 2016 Jun 5.Staals EL, Ferrari S, Donati DM, Palmerini E. Diffuse-type tenosynovial giant cell tumour: current treatment concepts and future perspectives. Eur J Cancer. 2016 Aug: 63:34-40. doi: 10.1016/j.ejca.2016.04.022. Epub 2016 Jun 5.Mastboom MJL, Verspoor FGM, Verschoor AJ, et al. Higher incidence rates than previously known in tenosynovial giant cell tumors. Acta Orthop. 2017 Dec;88(6):688- 694. doi: 10.1080/17453674.2017.1361126. Epub 2017 Aug 8.Mastboom MJL, Verspoor FGM, Verschoor AJ, et al. Higher incidence rates than previously known in tenosynovial giant cell tumors. Acta Orthop. 2017 Dec;88(6):688- 694. doi: 10.1080/17453674.2017.1361126. Epub 2017 Aug 8.Cupp JS, Miller MA, Montgomery KD, et al. Translocation and expression of CSF1 in pigmented villonodular synovitis, tenosynovial giant cell tumor, rheumatoid arthritis and other reactive synovitides. Am J Surg Pathol. 2007 Jun;31(6):970-6. doi: 10.1097/PAS.0b013e31802b86f8.Cupp JS, Miller MA, Montgomery KD, et al. Translocation and expression of CSF1 in pigmented villonodular synovitis, tenosynovial giant cell tumor, rheumatoid arthritis and other reactive synovitides. Am J Surg Pathol. 2007 Jun;31(6):970-6. doi: 10.1097/PAS.0b013e31802b86f8.West RB, Rubin BP, Miller MA, et al. A landscape effect in tenosynovial giantcell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. Proc Natl Acad Sci U S A. 2006 Jan 17;103(3): 690-5. doi: 10.1073/pnas.0507321103. Epub 2006 Jan 6.West RB, Rubin BP, Miller MA, et al. A landscape effect in tenosynovial giantcell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. Proc Natl Acad Sci U S A. 2006 Jan 17;103(3): 690-5. doi: 10.1073/pnas.0507321103. Epub 2006 Jan 6.Yudoh K, Matsuno H, Nezuka T, Kimura T. Different mechanisms of synovial hyperplasia in rheumatoid arthritis and pigmented villonodular synovitis: the role of telomerase activity in synovial proliferation. Arthritis Rheum. 1999 Apr;42(4):669-77. doi: 10.1002/1529-0131(199904)42:43.0.CO;2-V.Yudoh K, Matsuno H, Nezuka T, Kimura T. Different mechanisms of synovial hyperplasia in rheumatoid arthritis and pigmented villonodular synovitis: the role of telomerase activity in synovial proliferation. Arthritis Rheum. 1999 Apr;42(4):669-77. doi: 10.1002/1529-0131(199904)42:43.0.CO;2-V.Akinci O, Akalin Y, Incesu M, Eren A. Long-term results of surgical treatment of pigmented villonodular synovitis of the knee. Acta Orthop Traumatol Turc. 2011;45(3): 149-55. doi: 10.3944/AOTT.2011.2442.Akinci O, Akalin Y, Incesu M, Eren A. Long-term results of surgical treatment of pigmented villonodular synovitis of the knee. Acta Orthop Traumatol Turc. 2011;45(3): 149-55. doi: 10.3944/AOTT.2011.2442.Li Q, Che H, Li M, et al. Multifocal Pigmented villonodular synovitis in adult: a case report and review of the literature. Archives of medicine. 2015;7(2:6):1–3.Li Q, Che H, Li M, et al. Multifocal Pigmented villonodular synovitis in adult: a case report and review of the literature. Archives of medicine. 2015;7(2:6):1–3.Kramer DE, Frassica FJ, Frassica DA, Cosgarea AJ. Pigmented villonodular synovitis of the knee: diagnosis and treatment. J Knee Surg. 2009 Jul;22(3):243-54. doi: 10.1055/s-0030-1247756.Kramer DE, Frassica FJ, Frassica DA, Cosgarea AJ. Pigmented villonodular synovitis of the knee: diagnosis and treatment. J Knee Surg. 2009 Jul;22(3):243-54. doi: 10.1055/s-0030-1247756.Krause FG, Wroblewski JA, Younger ASE. Pigmented villonodular synovitis in both hindfeet. Can J Surg. 2009 Apr;52(2):E38-9.Krause FG, Wroblewski JA, Younger ASE. Pigmented villonodular synovitis in both hindfeet. Can J Surg. 2009 Apr;52(2):E38-9.Mastboom MJL, Verspoor FGM, Hanff DF, et al. Severity classification of Tenosynovial Giant Cell Tumours on MR imaging. Surg Oncol. 2018 Sep;27(3):544-550. doi: 10.1016/j.suronc.2018.07.002. Epub 2018 Jul 3.Mastboom MJL, Verspoor FGM, Hanff DF, et al. Severity classification of Tenosynovial Giant Cell Tumours on MR imaging. Surg Oncol. 2018 Sep;27(3):544-550. doi: 10.1016/j.suronc.2018.07.002. Epub 2018 Jul 3.Spanier D, Harrast M. Pigmented villonodular synovitis: an uncommon presentation of anterior hip pain. Am J Phys Med Rehabil. 2005 Feb;84(2):131-5. doi: 10.1097/01.phm.0000150794.33166.3a.Spanier D, Harrast M. Pigmented villonodular synovitis: an uncommon presentation of anterior hip pain. Am J Phys Med Rehabil. 2005 Feb;84(2):131-5. doi: 10.1097/01.phm.0000150794.33166.3a.Auregan JC, Bohu Y, Lefevre N, et al. Primary arthroscopic synovectomy for pigmented villo-nodular synovitis of the knee: recurrence rate and functional outcomes after a mean follow-up of seven years. Orthop Traumatol Surg Res. 2013 Dec;99(8):937-43. doi: 10.1016/j.otsr.2013.08.004. Epub 2013 Oct 23.Auregan JC, Bohu Y, Lefevre N, et al. Primary arthroscopic synovectomy for pigmented villo-nodular synovitis of the knee: recurrence rate and functional outcomes after a mean follow-up of seven years. Orthop Traumatol Surg Res. 2013 Dec;99(8):937-43. doi: 10.1016/j.otsr.2013.08.004. Epub 2013 Oct 23.Van der Heijden L, Gibbons CL, Dijkstra PD, et al. The management of diffuse-type giant cell tumour (pigmented villonodular synovitis) and giant cell tumour of tendon sheath (nodular tenosynovitis). J Bone Joint Surg Br. 2012 Jul;94(7):882-8. doi: 10.1302/0301-620X.94B7.28927.Van der Heijden L, Gibbons CL, Dijkstra PD, et al. The management of diffuse-type giant cell tumour (pigmented villonodular synovitis) and giant cell tumour of tendon sheath (nodular tenosynovitis). J Bone Joint Surg Br. 2012 Jul;94(7):882-8. doi: 10.1302/0301-620X.94B7.28927.Ravi V, Wang W, Araujo DM, et al. Imatinib in the treatment of tenosynovial giant-cell tumor and pigmented villonodular synovitis. J Clin Oncol. 2010;28(15 Suppl):10011.Ravi V, Wang W, Araujo DM, et al. Imatinib in the treatment of tenosynovial giant-cell tumor and pigmented villonodular synovitis. J Clin Oncol. 2010;28(15 Suppl):10011.Cassier PA, Italiano A, Gomez-Roca CA, et al. CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and doseexpansion phase 1 study. Lancet Oncol. 2015 Aug;16(8):949-56. doi: 10.1016/S1470-2045(15)00132-1. Epub 2015 Jul 12.Cassier PA, Italiano A, Gomez-Roca CA, et al. CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and doseexpansion phase 1 study. Lancet Oncol. 2015 Aug;16(8):949-56. doi: 10.1016/S1470-2045(15)00132-1. Epub 2015 Jul 12.Nassar WA, Bassiony AA, Elghazaly HA. Treatment of diffuse pigmented villonodular synovitis of the knee with combined surgical and radiosyn ovectomy. HSS J. 2009 Feb; 5(1):19-23. doi: 10.1007/s11420-008-9104-5. Epub 2008 Dec 19.Nassar WA, Bassiony AA, Elghazaly HA. Treatment of diffuse pigmented villonodular synovitis of the knee with combined surgical and radiosyn ovectomy. HSS J. 2009 Feb; 5(1):19-23. doi: 10.1007/s11420-008-9104-5. Epub 2008 Dec 19.Gu HF, Zhang SJ, Zhao C, et al. A comparison of open and arthroscopic surgery for treatment of diffuse pigmented villonodular synovitis of the knee. Knee Surg Sports Traumatol Arthrosc. 2014 Nov;22(11):2830-6. doi: 10.1007/s00167-014-2852-5. EpubGu HF, Zhang SJ, Zhao C, et al. A comparison of open and arthroscopic surgery for treatment of diffuse pigmented villonodular synovitis of the knee. Knee Surg Sports Traumatol Arthrosc. 2014 Nov;22(11):2830-6. doi: 10.1007/s00167-014-2852-5. EpubColman MW, Ye J, Weiss KR, et al. Does combined open and arthroscopic synovectomy for diffuse PVNS of the knee improve recurrence rates? Clin Orthop Relat Res. 2013 Mar; 471(3):883-90. doi: 10.1007/s11999-012-2589-8.Colman MW, Ye J, Weiss KR, et al. Does combined open and arthroscopic synovectomy for diffuse PVNS of the knee improve recurrence rates? Clin Orthop Relat Res. 2013 Mar; 471(3):883-90. doi: 10.1007/s11999-012-2589-8.Mastboom MJL, Palmerini E, Verspoor FGM, et al. Surgical outcomes of patients with diffuse-type tenosynovial giantcell tumours: an international, retrospective, cohort study. Lancet Oncol. 2019 Jun;20(6): 877-886. doi: 10.1016/S1470-2045(19)30100-7. Epub 2019 Apr 24.Mastboom MJL, Palmerini E, Verspoor FGM, et al. Surgical outcomes of patients with diffuse-type tenosynovial giantcell tumours: an international, retrospective, cohort study. Lancet Oncol. 2019 Jun;20(6): 877-886. doi: 10.1016/S1470-2045(19)30100-7. Epub 2019 Apr 24.Паньшин ГА. Пигментированный ворсинчато-узловой синовит. Вестник Российского научного центра рентгенрадиологии. 2016;16(2):2.Pan'shin GA. Pigmented villous-nodular synovitis. Vestnik Rossiiskogo nauchnogo tsentra rentgenradiologii. 2016;16(2):2. (In Russ.).Koca G, Ozsoy H, Atilgan HI, et al. Application of rhenium-186 radiosynovectomy in elbow diffuse pigmented villonodular synovitis – a case report with multiple joint involvement. Nucl Med Mol Imaging. 2012 Sep;46(3): 215-7. doi: 10.1007/s13139-012-0152-x. Epub 2012 Jul 13.Koca G, Ozsoy H, Atilgan HI, et al. Application of rhenium-186 radiosynovectomy in elbow diffuse pigmented villonodular synovitis – a case report with multiple joint involvement. Nucl Med Mol Imaging. 2012 Sep;46(3): 215-7. doi: 10.1007/s13139-012-0152-x. Epub 2012 Jul 13.Mollon B, Lee A, Busse JW, et al. The effect of surgical synovectomy and radiotherapy on the rate of recurrence of pigmented villonodular synovitis of the knee: an individual patient meta-analysis. Bone Joint J. 2015 Apr; 97-B(4):550-7. doi: 10.1302/0301-620X.97B4.34907.Mollon B, Lee A, Busse JW, et al. The effect of surgical synovectomy and radiotherapy on the rate of recurrence of pigmented villonodular synovitis of the knee: an individual patient meta-analysis. Bone Joint J. 2015 Apr; 97-B(4):550-7. doi: 10.1302/0301-620X.97B4.34907.

The authors declare that there are no conflicts of interest present.